Clinical & Translational

The test adds to a growing menu of approved assays for the cobas 4800 system.

The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.

In a 6,000-patient study, Eskenazi Health will assess whether PGx testing improves outcomes and saves money in a community that doesn't usually have access to genomic advances.

The partners will focus on early treatment and diagnosis of cancers in women's health and abdominal and blood cancers.

The company said the proceeds will be used to refine its core technology and improve manufacturing.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.